YANIKLER

MediGene AG

Application Filed: 2010-04-08

Trademark Application Details

Status

710

Dead/Cancelled

CANCELLED - SECTION 8

Research	OneLook Acronym Finder
Serial Number	85009184
Registration Number	3947037
Mark Drawing Code	4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form
Cancellation Code	2
Domestic Representative	Adrienne L. White
Attorney Name	Adrienne L. White
Attorney Docket Number	000337-019
Law Office Assigned	L20
Employee Name	CHOSID, ROBIN S

Timeline

2010-04-08	Application Filed
2011-02-01	Published for Opposition
2011-04-19	Location: PUBLICATION AND ISSUE SECTION
2011-04-19	Trademark Registered
2017-11-24	Cancelled
2017-11-24	Status: Dead/Cancelled
2018-07-08	Transaction Date

Trademark Applicants & Owners

Owner:	MediGene AG
Entity Statement	aktiengesellschaft
Address	Lochhamer Strasse 11 D-82152 Planegg/Martinsrie DE
Legal Entity Type
Legal Entity State	DE

Documents

Click the blue "Refresh" button to load certificates, specimines, application, and other documents.

Attorney of Record

ADRIENNE L. WHITE
WRB-IP LLP
PO BOX 476
WADSWORTH, OH 44282-0476

Good, Services, and Codes

International Codes:	5
U.S. Codes:	006,018,044,046,051,052

Type Code	Type
GS0051	pharmaceutical and veterinary preparations, namely, medicines, vaccines, and serums for the testing, prevention, treatment and diagnosis of tumor precursors, benign and malignant tumors, in particular, warts, genital warts, neuronal tumors, glioma, astrocytoma, colon carcinoma, ovarian carcinoma, cervical cancer, prostate carcinoma, basal cell carcinoma, squamous cell carcinoma, melanoma, kaposi's sarcoma, breast cancer, head and neck carcinomas, hepatocellular carcinoma, bronchial carcinoma, pancreatic tumours and renal tumours, autoimmune disorders, in particular rheumatoid arthritis, polyarthritis, crohn's disease, lupus erythematosus and multiple sclerosis, neurodegenerative disorders, in particular alzheimer's disease, huntington's disease, multiple sclerosis, parkinson's disease, schizophrenia, transmissible spongiform encephalopathy, bovine spongiform encephalopathy and/or creutzfeldt-jakob disease, rheumatic disorders, in particular rheumatoid arthritis, polychondritis, bechterew's disease, fibromyalgia and lupus erythematodes, allergic diseases, in particular allergies, allergic rhinitis, hay fever, asthma, atopic eczema and insect sting allergies, cardiovascular disorders, in particular hyperlipidaemia, coronary artery disorders, cardiac insufficiency, high blood pressure and obesity, skin diseases, in particular warts, genital warts, bowen's disease, actinic keratosis, seborrhoeic keratosis, psoriasis, dermatitis, eczema, acne, rosacea and herpes, infectious diseases, in particular viral infections, bacterial infections, parasitic infections and/or fungal infections, and ophthalmic disorders, in particular age-dependent macular degeneration, glaucoma and retinoblastoma; all of the above consisting of low-molecular active substances, liposomes, aptamers, nucleic acids, peptides, proteins, protein conjugates, antibodies, t-cell proteins, enzymes and enzyme preparations, hormones, hormone analogues, attenuated viruses, virus-type particles and plant extracts, in particular for oral, topical, intravenous and subcutaneous administration

Type Code

Type

GS0051

pharmaceutical and veterinary preparations, namely, medicines, vaccines, and serums for the testing, prevention, treatment and diagnosis of tumor precursors, benign and malignant tumors, in particular, warts, genital warts, neuronal tumors, glioma, astrocytoma, colon carcinoma, ovarian carcinoma, cervical cancer, prostate carcinoma, basal cell carcinoma, squamous cell carcinoma, melanoma, kaposi's sarcoma, breast cancer, head and neck carcinomas, hepatocellular carcinoma, bronchial carcinoma, pancreatic tumours and renal tumours, autoimmune disorders, in particular rheumatoid arthritis, polyarthritis, crohn's disease, lupus erythematosus and multiple sclerosis, neurodegenerative disorders, in particular alzheimer's disease, huntington's disease, multiple sclerosis, parkinson's disease, schizophrenia, transmissible spongiform encephalopathy, bovine spongiform encephalopathy and/or creutzfeldt-jakob disease, rheumatic disorders, in particular rheumatoid arthritis, polychondritis, bechterew's disease, fibromyalgia and lupus erythematodes, allergic diseases, in particular allergies, allergic rhinitis, hay fever, asthma, atopic eczema and insect sting allergies, cardiovascular disorders, in particular hyperlipidaemia, coronary artery disorders, cardiac insufficiency, high blood pressure and obesity, skin diseases, in particular warts, genital warts, bowen's disease, actinic keratosis, seborrhoeic keratosis, psoriasis, dermatitis, eczema, acne, rosacea and herpes, infectious diseases, in particular viral infections, bacterial infections, parasitic infections and/or fungal infections, and ophthalmic disorders, in particular age-dependent macular degeneration, glaucoma and retinoblastoma; all of the above consisting of low-molecular active substances, liposomes, aptamers, nucleic acids, peptides, proteins, protein conjugates, antibodies, t-cell proteins, enzymes and enzyme preparations, hormones, hormone analogues, attenuated viruses, virus-type particles and plant extracts, in particular for oral, topical, intravenous and subcutaneous administration

Trademark Filing History

Description	Date	Event Coding
NEW APPLICATION ENTERED IN TRAM	2010-04-12	1 NWAP I:Incoming Correspondence
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM	2010-04-13	2 NWOS I:Incoming Correspondence
ASSIGNED TO EXAMINER	2010-05-27	3 DOCK D:Assigned to Examiner
EXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED	2010-05-29	4 CPEA R:Renewal
EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED	2010-05-29	5 GEAP F:First Action
NOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED	2010-05-29	6 GEAN O:Outgoing Correspondence
TEAS RESPONSE TO OFFICE ACTION RECEIVED	2010-11-29	7 TROA I:Incoming Correspondence
ASSIGNED TO LIE	2010-12-21	8 ALIE A:Allowance for Publication
CORRESPONDENCE RECEIVED IN LAW OFFICE	2010-12-21	9 CRFA I:Incoming Correspondence
TEAS/EMAIL CORRESPONDENCE ENTERED	2010-12-21	10 TEME I:Incoming Correspondence
APPROVED FOR PUB - PRINCIPAL REGISTER	2010-12-22	11 CNSA O:Outgoing Correspondence
LAW OFFICE PUBLICATION REVIEW COMPLETED	2010-12-29	12 PREV O:Outgoing Correspondence
PUBLISHED FOR OPPOSITION	2011-02-01	13 PUBO A:Allowance for Publication
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED	2011-02-01	14 NPUB E:E-Mail
REGISTERED-PRINCIPAL REGISTER	2011-04-19	15 R.PR A:Allowance for Publication
CANCELLED SEC. 8 (6-YR)	2017-11-24	16 C8.. O:Outgoing Correspondence

Similar Marks

Mark Image Registration \| Serial	Company Trademark Application Date
YANIKLER 85009184 3947037 Dead/Cancelled	MediGene AG 2010-04-08
YANIKLER 76498487 2866214 Dead/Cancelled	MediGene AG 2003-03-19

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.